Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
- PMID: 24379612
- PMCID: PMC3870540
- DOI: 10.3748/wjg.v19.i47.8887
Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the majority of cases associated with persistent infection from hepatitis B virus (HBV) or hepatitis C virus (HCV). Natural history studies have identified risk factors associated with HCC development among chronic HBV and HCV infection. High-risk infected individuals can now be identified by the usage of risk predictive scores. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could also reduce the risk of HBV-related HCC. Concerning HCV infection, besides the advocation of universal precautions to reduce the rate of infection, pegylated interferon and ribavirin could also reduce the risk of HCV-related HCC among those achieving a sustained virologic response. Recently there has been mounting evidence on the role of chemopreventive agents in reducing HBV- and HCV-related HCC. The continued advances in the understanding of the molecular pathogenesis of HCC would hold promise in preventing this highly lethal cancer.
Keywords: Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Prevention; Vaccination.
Similar articles
-
Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?J Gastroenterol Hepatol. 2011 Feb;26(2):221-7. doi: 10.1111/j.1440-1746.2010.06576.x. J Gastroenterol Hepatol. 2011. PMID: 21070361
-
[Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma].Orv Hetil. 2009 Jan 4;150(1):19-26. doi: 10.1556/OH.2009.28529. Orv Hetil. 2009. PMID: 19091671 Review. Hungarian.
-
Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.J Gastroenterol Hepatol. 2010 Apr;25(4):657-63. doi: 10.1111/j.1440-1746.2009.06167.x. J Gastroenterol Hepatol. 2010. PMID: 20492323
-
Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.Gut. 2014 Mar;63(3):506-14. doi: 10.1136/gutjnl-2012-304370. Epub 2013 May 15. Gut. 2014. PMID: 23676440
-
Prevention of hepatocellular carcinoma in hepatitis B virus infection.J Gastroenterol Hepatol. 2009 Aug;24(8):1352-7. doi: 10.1111/j.1440-1746.2009.05985.x. J Gastroenterol Hepatol. 2009. PMID: 19702903 Review.
Cited by
-
Identification of HBV-MLL4 Integration and Its Molecular Basis in Chinese Hepatocellular Carcinoma.PLoS One. 2015 Apr 22;10(4):e0123175. doi: 10.1371/journal.pone.0123175. eCollection 2015. PLoS One. 2015. PMID: 25901726 Free PMC article.
-
Hepatitis B vaccination status and knowledge, attitude, and practice towards Hepatitis B virus among medical sciences students: A cross-sectional study.PLoS One. 2023 Nov 6;18(11):e0293822. doi: 10.1371/journal.pone.0293822. eCollection 2023. PLoS One. 2023. PMID: 37930973 Free PMC article.
-
Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular carcinoma.Front Med. 2019 Apr;13(2):250-258. doi: 10.1007/s11684-018-0632-1. Epub 2018 May 16. Front Med. 2019. PMID: 29770948
-
Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors.Antiviral Res. 2016 Nov;135:24-30. doi: 10.1016/j.antiviral.2016.09.009. Epub 2016 Sep 28. Antiviral Res. 2016. PMID: 27693161 Free PMC article.
-
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?Hum Vaccin Immunother. 2017 Mar 4;13(3):528-532. doi: 10.1080/21645515.2016.1244149. Epub 2016 Nov 3. Hum Vaccin Immunother. 2017. PMID: 27808593 Free PMC article.
References
-
- Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol. 2013;35:111–120. - PubMed
-
- Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics. 2013;102:74–83. - PubMed
-
- Zemel R, Issachar A, Tur-Kaspa R. The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis. 2011;15:261–279, vii-x. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical